Fulcrum Therapeutics, Inc. (FULC) gains Tang Capital as 10.4% shareholder
Rhea-AI Filing Summary
Tang Capital Management, LLC and related investment entities report beneficial ownership of 6,913,329 shares of Fulcrum Therapeutics, Inc. common stock, representing 10.4% of the class based on 66,633,321 shares outstanding as of April 20, 2026. All reported shares are held with shared voting and dispositive power, with no sole voting or dispositive authority for any filer.
Within this aggregate position, Tang Capital Partners, LP, Tang Capital Partners International, LP, Tang Capital Partners III, Inc. and Tang Capital Partners IV, Inc. respectively report shared power over 1,630,142, 2,160,423, 1,630,127 and 1,492,637 shares, all under the oversight of Kevin Tang.
Positive
- None.
Negative
- None.
Key Figures
Beneficial ownership: 6,913,329 shares
Ownership percentage: 10.4 %
Shares outstanding: 66,633,321 shares
+4 more
7 metrics
Beneficial ownership
6,913,329 shares
Shares of Fulcrum Therapeutics common stock beneficially owned by Tang Capital filers
Ownership percentage
10.4 %
Percentage of Fulcrum Therapeutics common stock class beneficially owned
Shares outstanding
66,633,321 shares
Fulcrum Therapeutics common shares outstanding as of April 20, 2026
TCP shared voting power
1,630,142 shares
Shares over which Tang Capital Partners, LP has shared voting and dispositive power
TCPI shared voting power
2,160,423 shares
Shares over which Tang Capital Partners International, LP has shared voting and dispositive power
TCP III shared voting power
1,630,127 shares
Shares over which Tang Capital Partners III, Inc. has shared voting and dispositive power
TCP IV shared voting power
1,492,637 shares
Shares over which Tang Capital Partners IV, Inc. has shared voting and dispositive power
Key Terms
beneficially owned, shared voting power, dispositive power, Schedule 13G/A
4 terms
beneficially owned regulatory
"Item 4 lists the amount beneficially owned: 6,913,329"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
dispositive power regulatory
"0 sole dispositive power and 6,913,329 shares of shared dispositive power"
Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.
Schedule 13G/A regulatory
"Form type is identified as SCHEDULE 13G/A in the header"
A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What percentage of Fulcrum Therapeutics (FULC) does Tang Capital beneficially own?
Tang Capital–related filers beneficially own 10.4% of Fulcrum Therapeutics’ common stock. This corresponds to 6,913,329 shares, calculated using 66,633,321 shares outstanding as of April 20, 2026, with all voting and dispositive power reported as shared.
How is the 10.4% ownership in Fulcrum Therapeutics (FULC) calculated?
The 10.4% ownership is based on 6,913,329 shares beneficially owned divided by 66,633,321 Fulcrum Therapeutics shares outstanding as of April 20, 2026, as referenced from the company’s Form 10-Q, providing the denominator for the ownership percentage.
What are the individual Fulcrum Therapeutics (FULC) positions of the Tang Capital funds?
Tang Capital Partners reports shared power over 1,630,142 shares, Tang Capital Partners International 2,160,423 shares, Tang Capital Partners III 1,630,127 shares, and Tang Capital Partners IV 1,492,637 shares, all counted within the aggregate 6,913,329-share beneficial ownership position.